bluebird bio, Inc. (BLUE): Price and Financial Metrics

BLUE POWR Grades

• BLUE scores best on the Growth dimension, with a Growth rank ahead of 90.31% of US stocks.
• BLUE's strongest trending metric is Momentum; it's been moving up over the last 177 days.
• BLUE's current lowest rank is in the Stability metric (where it is better than 1.08% of US stocks).

BLUE Stock Summary

• The capital turnover (annual revenue relative to shareholder's equity) for BLUE is -0.23 -- better than only 6.15% of US stocks.
• With a year-over-year growth in debt of 53.23%, BLUEBIRD BIO INC's debt growth rate surpasses 82.51% of about US stocks.
• Revenue growth over the past 12 months for BLUEBIRD BIO INC comes in at -166.63%, a number that bests merely 0.26% of the US stocks we're tracking.
• If you're looking for stocks that are quantitatively similar to BLUEBIRD BIO INC, a group of peers worth examining would be RGTI, ENVX, LASR, LAZR, and SNAP.
• BLUE's SEC filings can be seen here. And to visit BLUEBIRD BIO INC's official web site, go to www.bluebirdbio.com.

BLUE Valuation Summary

• In comparison to the median Healthcare stock, BLUE's price/earnings ratio is 103.45% lower, now standing at -0.8.
• BLUE's EV/EBIT ratio has moved up 11.9 over the prior 119 months.

Below are key valuation metrics over time for BLUE.

BLUE Growth Metrics

The year over year price growth rate now stands at -88.6%.
• Its 3 year net income to common stockholders growth rate is now at -21.62%.
• Its 4 year net income to common stockholders growth rate is now at -199.98%.

Over the past 15 months, BLUE's revenue has gone down $85,993,000.

The table below shows BLUE's growth in key financial areas (numbers in millions of US dollars).

Date	Revenue	Operating Cash Flow	Net Income to Common Stock
2022-09-30	-35.746	-436.405	-453.862
2022-06-30	-13.14	-506.318	-594.158
2022-03-31	-7.187	-557.608	-735.722
2021-12-31	3.662	-635.639	-819.378
2021-09-30	53.651	-651.107	-864.2
2021-06-30	50.247	-652.948	-842.129

BLUE's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.

• BLUE has a Quality Grade of D, ranking ahead of 15.84% of graded US stocks.
• BLUE's asset turnover comes in at 0.029 -- ranking 353rd of 682 Pharmaceutical Products stocks.
• NERV, OTLC, and BPMC are the stocks whose asset turnover ratios are most correlated with BLUE.

The table below shows BLUE's key quality metrics over time.